A global double-masked, placebo-controlled trial to evaluate the safety and efficacy of a subcutaneously delivered dose of lonigutamab in Thyroid Eye Disease (TED).

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 Jan 2025 New trial record
06 Jan 2025 According to ACELYRIN, INC media release, ACELYRIN held an End of Phase 2 (EOP2) meeting with the United States Food and Drug Administration (FDA) in Q3 2024 and gained alignment on the proposed LONGITUDE-1 and LONGITUDE-2 Phase 3 trial designs.
06 Jan 2025 According to ACELYRIN, INC media release, Initiation of this trial is expected in Q1 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com